For research use only. Not for therapeutic Use.
ABT-072（Cat No.:I000711） is a compound that holds potential as a treatment for Hepatitis C virus (HCV) infection. It functions as a NS5B polymerase inhibitor, targeting the viral enzyme responsible for replication of the HCV genome. By inhibiting NS5B polymerase, ABT-072 aims to disrupt the replication process of the virus, thereby reducing viral load and potentially controlling the infection.
| Catalog Number | I000711 |
| CAS Number | 1132936-00-5 |
| Synonyms | ABT-072; ABT 072; ABT072.;(E)-N-(4-(3-(tert-butyl)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxystyryl)phenyl)methanesulfonamide |
| Molecular Formula | C24H27N3O5S |
| Purity | ≥95% |
| Target | HCV NS5B polymerase inhibitor |
| Solubility | Soluble in DMSO |
| Storage | -20°C |
| IUPAC Name | N-[4-[(E)-2-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl]ethenyl]phenyl]methanesulfonamide |
| InChI | InChI=1S/C24H27N3O5S/c1-24(2,3)20-15-19(27-13-12-21(28)25-23(27)29)14-17(22(20)32-4)9-6-16-7-10-18(11-8-16)26-33(5,30)31/h6-15,26H,1-5H3,(H,25,28,29)/b9-6+ |
| InChIKey | XMZSTQYSBYEENY-RMKNXTFCSA-N |
| SMILES | CC(C)(C)C1=CC(=CC(=C1OC)C=CC2=CC=C(C=C2)NS(=O)(=O)C)N3C=CC(=O)NC3=O |
| Reference | </br>1:Assessing Supersaturation and Its Impact on In Vivo Bioavailability of a Low-Solubility Compound ABT-072 With a Dual pH, Two-Phase Dissolution Method. Shi Y, Erickson B, Jayasankar A, Lu L, Marsh K, Menon R, Gao P.J Pharm Sci. 2016 Sep;105(9):2886-95. doi: 10.1016/j.xphs.2016.04.036. Epub 2016 Jun 16. PMID: 27321234 </br>2:A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1. Lawitz E, Poordad F, Kowdley KV, Cohen DE, Podsadecki T, Siggelkow S, Larsen L, Menon R, Koev G, Tripathi R, Pilot-Matias T, Bernstein B.J Hepatol. 2013 Jul;59(1):18-23. doi: 10.1016/j.jhep.2013.02.009. Epub 2013 Feb 22. PMID: 23439262 |
